clinical trial · NCT06208150
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Janssen Research & Development, LLC·phase3·active not recruiting·n = 838
Multiple MyelomaTalquetamabPomalidomideTeclistamabElotuzumabDexamethasoneBortezomib
brief summary
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
started
Jan 22, 2024
primary completion
Apr 1, 2026
completion
Dec 31, 2028
last updated
Jul 30, 2026
official title
64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol